Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma <i>in vivo</i>.

ABSTRACT: Late-stage melanoma can metastasize to organs beyond the skin, such as lungs, liver, brain, and bone, resulting in reduced patient survival time. The incidence of melanoma is currently growing worldwide, and novel therapeutic options are needed to prevent its dissemination and to improve therapeutic results. This paper describes the use of small interfering RNA (siRNA) to silence expression of TGFβ1 and VEGFR2 as an alternative approach for melanoma treatment. These two therapeutic targets have been well-documented in tumor immune modulation and tumor angiogenesis within the tumor microenvironment (TME). Two potent siRNA candidates targeting TGFβ1 or VEGFR2 were identified with 100% identity to sequences of mouse, non-human primate (NHP), and humans. The combination of the two siRNAs was f

SUBMITTER: Wang D 

PROVIDER: S-EPMC12813501 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature